HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Aurobindo Pharma’s arm gets EIR for Unit-IV facility in Andhra Pradesh
Mar-12-2026

Aurobindo Pharma’s wholly owned subsidiary -- APL Healthcare has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-IV, located at Palchur village, Andhra Pradesh. The USFDA has classified the facility as ‘Voluntary Action Indicated’ (VAI).

The USFDA had conducted an inspection of the said facility from December 08 to December 17, 2025 and issued a ‘Form 483’ with 05 observations. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>